ONCO (Onconetix) Change In Receivables : $0.05 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Onconetix Change In Receivables?

Onconetix's change in receivables for the quarter that ended in Sep. 2024 was $0.08 Mil. It means Onconetix's Accounts Receivable declined by $0.08 Mil from Jun. 2024 to Sep. 2024 .

Onconetix's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.06 Mil. It means Onconetix's Accounts Receivable increased by $0.06 Mil from Dec. 2022 to Dec. 2023 .

Onconetix's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.10 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Onconetix's Days Sales Outstanding for the three months ended in Sep. 2024 was 21.97.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Onconetix's liquidation value for the three months ended in Sep. 2024 was $-20.42 Mil.

Onconetix Change In Receivables Historical Data

The historical data trend for Onconetix's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix Change In Receivables Chart

Onconetix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.01

-0.04

-0.12

-0.06

Onconetix Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial												-	-	-0.12	0.09	0.08

Onconetix Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

Onconetix (NAS:ONCO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Onconetix's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.098	/	0.407	*	91
=	21.97

2. In Ben Graham's calculation of liquidation value, Onconetix's accounts receivable are only considered to be worth 75% of book value:

Onconetix's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.341	-	20.897	+	0.75 * 0.098	+	0.5 * 0.122
=	-20.42

Onconetix Change In Receivables Related Terms

Thank you for viewing the detailed overview of Onconetix's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Onconetix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202

Website

https://www.onconetix.com

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Executives

Neil J Campbell	director, officer: Chief Executive Officer	225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon	officer: Chief Financial Officer	316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic	director	BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc	10 percent owner	2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc	other: Manager-Cinti Cornerstone Inv.	2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez	10 percent owner, officer: CEO	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson	officer: Chief Business Officer	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield	officer: CFO	11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable	director	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202